Toward in vivo -relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia
Preprint
Abstract
The human ether-a-go-go-related voltage-gated cardiac ion channel (commonly known as hERG) conducts the rapid outward repolarizing potassium current in cardiomyocytes (I Kr ). Inadvertent blockade of this channel by drug-like molecules represents a key challenge in pharmaceutical R&D due to frequent overlap between the structure-activity relationships of hERG and many primary targets. Building on our previous work, together with recent cryo-EM structures of hERG, we set about to better understand the energetic and structural basis of promiscuous blocker-hERG binding in the context of Biodynamics theory. We propose a two-step blocker binding process consisting of: Diffusion of a single fully solvated blocker copy into a large cavity lined by the intracellular cyclic nucleotide binding homology domain (the initial capture step). Occupation of this cavity is a necessary but insufficient condition for ion current disruption. Translocation of the captured blocker along the channel axis (the I Kr disruption step), such that: The head group, consisting of a quasi-linear moiety, projects into the open pore, accompanied by partial de-solvation of the binding interface. One tail moiety packs along a kink between the S6 helix and proximal C-linker helix adjacent to the intra-cellular entrance of the pore, likewise accompanied by mutual de-solvation of the binding interface (noting that the association barrier is comprised largely of the total head + tail group de-solvation cost). Blockers containing a highly planar moiety that projects into a putative constriction zone within the closed channel become trapped upon closing, as do blockers terminating prior to this region. A single captured blocker molecule may associate and dissociate from the pore many times before exiting the CNBHD cavity. Lastly, we highlight possible flaws in the current hERG safety index (SI) and propose an alternate in vivo-relevant strategy factoring in: Benefit/risk. The predicted arrhythmogenic fractional hERG occupancy (based on action potential simulations of the undiseased human ventricular cardiomyocyte). Alteration of the safety threshold due to underlying disease. Risk of exposure escalation toward the predicted arrhythmic limit due to patient-to-patient pharmacokinetic variability, drug-drug interactions, overdose, and use for off-label indications in which the hERG safety parameters may differ from their on-label counterparts.Keywords
All Related Versions
- Published version: PLOS ONE, 15 (11), e0234946.
This publication has 47 references indexed in Scilit:
- Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental ValidationPLOS Computational Biology, 2011
- Trapping and dissociation of propafenone derivatives in HERG channelsBritish Journal of Pharmacology, 2010
- New hypotheses about the structure–function of proprotein convertase subtilisin/kexin type 9: Analysis of the epidermal growth factor‐like repeat A docking site using WaterMapProteins: Structure, Function, and Bioinformatics, 2010
- hERG in vitro interchange factors—development and verificationToxicology Mechanisms and Methods, 2009
- Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused byPlasmodium vivaxAntimicrobial Agents and Chemotherapy, 2009
- State dependent dissociation of HERG channel inhibitorsBritish Journal of Pharmacology, 2007
- Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug developmentCardiovascular Research, 2003
- Long QT syndromes and torsade de pointesThe Lancet, 1999
- Blockade of cardiac sodium channels. Competition between the permeant ion and antiarrhythmic drugs.Journal of Clinical Investigation, 1992
- Immobilisation of gating charge by a substance that simulates inactivationNature, 1978